Created in Toulouse in 2017, Sêmeia develops simple, intuitive and effective support solutions for patients suffering from serious or chronic illnesses.
The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from France have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases.
The EFFI-CLIN project, of which the company HISTALIM is a partner, aims to offer a new cancer immunotherapy adapted to the immunological profile of each tumor according to the concept of personalized medicine by targeting a new generation of immune checkpoints.
Do you accept the deposit and reading of cookies to allow us to analyze your browsing anonymously and measure the audience of our website?OuiNonPrivacy Policy
You can revoke your consent at any time using the “Revoke Consent” button.Revoke consent